| |
Multivariablea HR (95% CI) – Stage I
|
Multivariablea HR (95% CI) – Stage II/III
|
|---|
|
Tumor type
|
|
GCTs
|
Ref.
|
Ref.
|
|
SCSTs
|
1.06 (0.60–1.86)
|
3.28 (1.88–5.73)***
|
|
Age (per 5-year increase)
|
1.23 (1.20–1.26)***
|
1.13 (1.10–1.16)***
|
|
Race/ethnicity
|
|
Non-Hispanic White
|
Ref.
|
Ref.
|
|
Non-Hispanic Black
|
1.18 (0.80–1.72)
|
1.13 (0.81–1.56)
|
|
Hispanic/other
|
1.14 (0.95–1.38)
|
1.12 (0.94–1.32)
|
|
Insurance
|
|
Private insurance
|
Ref.
|
Ref.
|
|
Uninsured
|
2.58 (2.08–3.21)***
|
2.07 (1.72–2.50)***
|
|
Medicaid/Medicare/other government insurance
|
3.15 (2.64–3.75)***
|
2.31 (1.97–2.70)***
|
|
Income (per year)
|
|
< $38,000
|
Ref.
|
Ref.
|
|
$38,000–$62,999
|
0.92 (0.74–1.15)
|
0.96 (0.79–1.16)
|
|
> $63,000
|
0.74 (0.56–0.98)*
|
0.77 (0.61–1.02)
|
|
Percent in ZIP code without a high school diploma
|
|
> 21%
|
Ref.
|
Ref.
|
|
7–20.9%
|
0.87 (0.70–1.07)
|
0.80 (0.67–0.97)*
|
|
< 7%
|
0.80 (0.61–1.06)
|
0.68 (0.52–0.88)**
|
|
Residence
|
|
Metropolitan
|
Ref.
|
Ref.
|
|
Urban/rural
|
1.18 (0.98–1.42)
|
1.09 (0.91–1.29)
|
|
Charlson-Deyo comorbidity score
|
|
0
|
Ref.
|
Ref.
|
|
≥ 1
|
2.03 (1.64–2.51)***
|
2.03 (1.68–2.45)***
|
- aThe following variables were included in the multivariable analysis: tumor type, age, diagnosis year, race/ethnicity, insurance, yearly income, percent in ZIP code without a high school diploma, residence, Charlson-Deyo comorbidity score
